Back to Search Start Over

Click Therapeutics Receives FDA Breakthrough Device Designation for Prescription Digital Therapeutic to Treat Episodic Migraine

Source :
Business Wire. December 16, 2022
Publication Year :
2022

Abstract

NEW YORK -- Click Therapeutics, Inc. ('Click'), a leader in Digital Therapeutics[TM] as prescription medical treatments, today announced that it has received Breakthrough Device Designation from the U.S. Food and [...]

Details

Language :
English
Database :
Gale General OneFile
Journal :
Business Wire
Publication Type :
News
Accession number :
edsgcl.730242360